IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
Jiang, Qian; Xu, Lan-Ping; Liu, Dai-Hong; Liu, Kai-Yan; Chen, Shan-Shan; Jiang, Bin; Jiang, Hao; Chen, Huan; Chen, Yu-Hong; Han, Wei; Zhang, Xiao-Hui; Wang, Yu; Qin, Ya-Zhen; Liu, Yan-Rong; Lai, Yue-Yun; Huang, Xiao-Jun
刊名BLOOD
2011-03-17
DOI10.1182/blood-2010-09-308510
117期:11页:3032-3040
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]CHRONIC MYELOID-LEUKEMIA ; ABL TYROSINE KINASE ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; WORLD-HEALTH-ORGANIZATION ; MARROW-TRANSPLANTATION ; CYTOGENETIC RESPONSES ; BLAST CRISIS ; FOLLOW-UP ; PHILADELPHIA-CHROMOSOME ; WORKING PARTY
英文摘要

The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) versus allo-HSCT (n = 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 months, hemoglobin < 100 g/L, and peripheral blood blasts > 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with 6-year event-free survival (EFS), OS, and PFS rates of more than 80.0%. Intermediate-risk (any factor) patients showed no difference in EFS and OS, but 6-year PFS rates were 55.7% versus 92.9% (P = .047) with imatinib versus allo-HSCT, respectively. Among high-risk (at least 2 factors) patients, imatinib was by far inferior to allo-HSCT, with 5-year EFS, OS, and PFS rates of 9.3% versus 66.7% (P = .034), 17.7% versus 100% (P = .008), and 18.8% versus 100% (P = .006), respectively. We conclude that allo-HSCT confers significant survival advantages for high-and intermediate-risk patients with AP-CML compared with imatinib treatment; however, the outcomes of the 2 therapies are equally good in low-risk patients. All trials were registered with the Chinese Clinical Trial Registry (www.chictr.org) as CHiCTR-TNC-10000955. (Blood. 2011; 117(11): 3032-3040)

语种英语
WOS记录号WOS:000288496300012
项目编号30725038 ; IRT0702
资助机构National Outstanding Young Scientists&prime ; Foundation of China ; University of China
引用统计
被引频次:42[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53542
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
医学人文研究院/公共教学部_哲学与社会科学系
北京大学临床肿瘤学院_移植与免疫治疗病区
作者单位Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Qian,Xu, Lan-Ping,Liu, Dai-Hong,et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase[J]. BLOOD,2011,117(11):3032-3040.
APA Jiang, Qian.,Xu, Lan-Ping.,Liu, Dai-Hong.,Liu, Kai-Yan.,Chen, Shan-Shan.,...&Huang, Xiao-Jun.(2011).Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.BLOOD,117(11),3032-3040.
MLA Jiang, Qian,et al."Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase".BLOOD 117.11(2011):3032-3040.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Qian]的文章
[Xu, Lan-Ping]的文章
[Liu, Dai-Hong]的文章
百度学术
百度学术中相似的文章
[Jiang, Qian]的文章
[Xu, Lan-Ping]的文章
[Liu, Dai-Hong]的文章
必应学术
必应学术中相似的文章
[Jiang, Qian]的文章
[Xu, Lan-Ping]的文章
[Liu, Dai-Hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。